Sanjaya Singh is the Founder and Chief Scientific Officer of Third Arc Bio, with over 25 years of expertise in biotherapeutics. He has a proven track record of innovation across multiple therapeutic areas, including immunology, oncology, retinal, metabolic, and neurological diseases. Throughout his career, he has developed novel biologics, many of which have received FDA breakthrough designations. He is a co-inventor of several key molecules, including SKYRIZI®, EBGLYSS™, PRAXBIND®, ligelizumab, and lampalizumab

Previously, Sanjaya served as Head of Janssen Biotherapeutics, where he led the global therapeutics discovery organization and set the strategic direction for expanding Johnson & Johnson’s biotherapeutic portfolio. Prior to this, he was Vice President of Biotherapeutics Discovery at Boehringer Ingelheim, where he built and led a global team to establish a competitive and productive preclinical and clinical pipeline. Sanjaya began his industry career at Tanox Inc., where he headed Biotherapeutics until the company was acquired by Genentech.

In addition to his leadership roles, Sanjaya co-founded Aliada Therapeutics, a neuroscience and blood-brain barrier platform company recently acquired by AbbVie. He also serves as a Venture Partner at Omega Funds, a prominent life sciences investment firm. His early career includes academic experience at the Institute of Life Sciences in India. Sanjaya has authored numerous peer-reviewed publications and holds over 60 patents, with contributions spanning basic research, platform technologies, and biologic molecules.

Sanjaya earned his Ph.D. in Molecular Biology from Banaras Hindu University and completed postdoctoral research at University of Texas MD Anderson Cancer Center.